List view / Grid view
The company’s new acquisition, valued up to $1 billion, supports…
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
Over half of patients were alive three years post-treatment with…
Over half of patients were alive three years post-treatment with the monoclonal antibody (mAb) in AstraZeneca’s Phase III trial, data shows.
AstraZeneca has released new clinical data demonstrating the first BTK…
AstraZeneca has released new clinical data demonstrating the first BTK inhibitor to show a favourable trend in overall survival versus standard-of-care chemoimmunotherapy in adults with untreated mantle cell lymphoma (MCL).
Results from AstraZeneca’s LAURA Phase III trial “represent a major…
Results from AstraZeneca’s LAURA Phase III trial “represent a major advance for [certain] patients with Stage III EGFR-mutated lung cancer".
The new acquisition grants AstraZeneca rights to a new CAR-T…
The new acquisition grants AstraZeneca rights to a new CAR-T cell therapy with a differentiated manufacturing process that could provide a potential best-in-class blood cancer treatment.
Astrazeneca’s small molecule tyrosine kinase inhibitor reduced the risk of…
Astrazeneca’s small molecule tyrosine kinase inhibitor reduced the risk of death by 51 percent in non-small cell lung cancer (NSCLC), a major Phase III study has shown.
AstraZeneca is set to acquire Neogene Therapeutics to advance T-cell…
AstraZeneca is set to acquire Neogene Therapeutics to advance T-cell receptor therapies for hard-to-treat cancers like solid tumours.
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall…
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
Patients treated with Imfinzi and chemotherapy experienced a 20 percent…
Patients treated with Imfinzi and chemotherapy experienced a 20 percent reduction in the risk of death versus chemotherapy alone.
Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus…
Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.
Lynparza with abiraterone is the first PARP inhibitor to demonstrate…
Lynparza with abiraterone is the first PARP inhibitor to demonstrate clinical benefit in combination with a hormonal agent in this setting.
Imfinizi™ and tremelimumab in combination with chemotherapy improved non-small lung…
Imfinizi™ and tremelimumab in combination with chemotherapy improved non-small lung cancer (NSCLC) survival by 23 percent in a Phase III study.
Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase…
Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine.
Pharma executives are committed to bringing drugs to market to…
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
A Phase II expansion of the ongoing TATTON trial has…
20 June 2016 | By Victoria White, Digital Content Producer
A Phase II expansion of the ongoing TATTON trial has been initiated to evaluate savolitinib (AZD6094) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients.
